Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Genentech will receive $62 million from the U.S. Biomedical Advanced Research & Development Authority (BARDA) to help develop a flu treatment and a drug for mustard agent exposure. The bulk of the cash will be distributed over five years to support clinical studies of baloxavir marboxil, an antiviral for people who have been hospitalized because of seasonal or pandemic flu. Some $19 million will go to develop alteplase, a drug already approved for heart attacks and stroke that shows promise in treating lung damage after mustard agent inhalation.
This article has been sent to the following recipient: